Summit Therapeutics (SMMT) Cash from Operations (2017 - 2026)
Summit Therapeutics' (SMMT) quarterly Cash from Operations came in at 141124000.0 in Q2 2026, down 111.44% YoY from 1233522820.32 in Q2 2025, and down 15.4% on a QoQ basis from 122291000.0 in Q1 2026.
Summit Therapeutics (SMMT) Cash from Operations (2017 - 2026) Analysis & Trends
Summit Therapeutics (SMMT) has 10 years of Cash from Operations data on file, last reported at 141124000.0 in Q2 2026.
- Quarterly Cash from Operations fell 111.44% year-over-year to 141124000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 458433000.0 (down 121.59% YoY) and the FY2025 annual result came in at 322930000.0, down 127.25% from the prior year.
- Cash from Operations retreated to 141124000.0 in Q2 2026, from 122291000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 5191000.0 in Q4 2022 to a low of 141124000.0 in Q2 2026.
- A 5-year average of 47044055.56 and a median of 30215500.0 in 2024 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations surged 156.55% — and 2023, when it plunged 474.86%.
- Tracing SMMT's Cash from Operations over 5 years: stood at 5191000.0 in 2022, then sank by 474.86% to 19459000.0 in 2023, then tumbled by 150.13% to 48673000.0 in 2024, then tumbled by 109.43% to 101938000.0 in 2025, then tumbled by 38.44% to 141124000.0 in 2026.
- The last three Cash from Operations figures came in at 141124000.0 (Q2 2026), 122291000.0 (Q1 2026), and 101938000.0 (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - | -141.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -141.12 Mn |
| Jun 30, 2026 | -141.12 Mn |
| Mar 31, 2026 | -122.29 Mn |
| Mar 31, 2026 | -122.29 Mn |
| Dec 31, 2025 | -101.94 Mn |
| Dec 31, 2025 | -101.94 Mn |
| Sep 30, 2025 | -93.08 Mn |
| Sep 30, 2025 | -93.08 Mn |
| Jun 30, 2025 | -66.74 Mn |
| Jun 30, 2025 | -66.74 Mn |
| Mar 31, 2025 | -61.17 Mn |
| Mar 31, 2025 | -61.17 Mn |
| Dec 31, 2024 | -48.67 Mn |
| Dec 31, 2024 | -48.67 Mn |
| Sep 30, 2024 | -30.30 Mn |
| Sep 30, 2024 | -30.30 Mn |
| Jun 30, 2024 | -33.00 Mn |
| Jun 30, 2024 | -33.00 Mn |
| Mar 31, 2024 | -30.13 Mn |
| Mar 31, 2024 | -30.13 Mn |